Category: Treatment

    • Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis.
    • Stemmer A, Shafran I, Stemmer SM, Tsoref D.
    • Cancers (Basel). 2020 Oct 18;12(10):E3026. doi: 10.3390/cancers12103026.

    • LitAlert ~~ GeneLit.com

    • Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry.
    • Michels J, Genestie C, Dunant A, Caron O, Lanoy E, Colomba E, Pommeret F, Rey A, Gouy S, Duvillard P, Le Teuff G, Larue C, Savoye AM, Lhommé C, Leary A, Morice P, Pautier P.
    • Gynecol Oncol. 2020 Oct 12:S0090-8258(20)33960-3. doi: 10.1016/j.ygyno.2020.09.050. Epub ahead of print.

    • Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data.
    • Sigorski D, Izycka-Swieszewska E, Bodnar L.
    • Target Oncol. 2020 Oct 12. doi: 10.1007/s11523-020-00756-4. Epub ahead of print.

    • The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
    • Haunschild CE, Tewari KS.
    • Gynecol Oncol. 2020 Oct 11:S0090-8258(20)33953-6. doi: 10.1016/j.ygyno.2020.09.043. Epub ahead of print.
    • Review

    • LitAlert ~~ GeneLit.com

    • Novel mutations in BRCA2 intron 11 and overexpression of COX-2 and BIRC3 mediate cellular resistance to PARP inhibitors.
    • Chen HD, Guo N, Song SS, Chen CH, Miao ZH, He JX.
    • Am J Cancer Res. 2020 Sep 1;10(9):2813-2831.

    • Somatic mutation profiling in BRCA-negative breast and ovarian cancer patients by multigene panel sequencing.
    • Kwong A, Cheuk IW, Shin VY, Ho CY, Au CH, Ho DN, Wong EY, Yu SW, Chen J, Chan KK, Ngan HY, Chan TL, Ma ES.
    • Am J Cancer Res. 2020 Sep 1;10(9):2919-2932.

    • LitAlert ~~ GeneLit.com

    • Astrophysics Meets Breast Cancer Advocacy.
    • Nance S.
    • FORCE. Blog. 2020 Oct 8.

    • Tumor and germline next generation sequencing in high grade serous cancer: experience from a large population-based testing program.
    • Care M, McCuaig J, Clarke B, Grenier S, Kim RH, Rouzbahman M, Stickle N, Bernardini M, Stockley TL.
    • Mol Oncol. 2020 Oct 8. doi: 10.1002/1878-0261.12817. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Effect of germline mutations in homologous recombination repair genes on overall survival of patients with pancreatic adenocarcinoma.
    • Yadav S, Kasi PM, Bamlet WR, Ho TP, Polley EC, Hu C, Hart SN, Rabe KG, Boddicker NJ, Gnanaolivu RD, Lee KY, Lindstrom T, Petersen GM, Couch FJ, McWilliams RR.
    • Clin Cancer Res. 2020 Oct 7:clincanres.1788.2020. doi: 10.1158/1078-0432.CCR-20-1788. Epub ahead of print.

    • Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer.
    • Lincoln SE, Nussbaum RL, Kurian AW, Nielsen SM, Das K, Michalski S, Yang S, Ngo N, Blanco A, Esplin ED.
    • JAMA Netw Open. 2020 Oct 1;3(10):e2019452. doi: 10.1001/jamanetworkopen.2020.19452.

    • LitAlert ~~ GeneLit.com

    • Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays.
    • Sadeghi F, Asgari M, Matloubi M, Ranjbar M, Karkhaneh Yousefi N, Azari T, Zaki-Dizaji M.
    • Biol Proced Online. 2020 Oct 1;22:23. doi: 10.1186/s12575-020-00133-5.

    • Advances in epithelial ovarian cancer.
    • Neesham D, Richards A, McGauran M.
    • Aust J Gen Pract. 2020 Oct;49(10):665-669.

    • ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
    • Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, Chang DK, Garsed DW, Jonkers J, Ledermann JA, Nik-Zainal S, Ray-Coquard I, Shah SP, Matias-Guiu X, Swisher EM, Yates LR.
    • Ann Oncol. 2020 Sep 28:S0923-7534(20)42164-7. doi: 10.1016/j.annonc.2020.08.2102. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Frequency and molecular characteristics of PALB2-associated cancers in Russian patients.
    • Preobrazhenskaya EV, Shleykina AU, Gorustovich OA, Martianov AS, Bizin IV, Anisimova EI, Sokolova TN, Chuinyshena SA, Kuligina ES, Togo AV, Belyaev AM, Ivantsov AO, Sokolenko AP, Imyanitov EN.
    • Int J Cancer. 2020 Sep 30. doi: 10.1002/ijc.33317. Epub ahead of print.

    • Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
    • Bodily WR, Shirts BH, Walsh T, Gulsuner S, King MC, Parker A, Roosan M, Piccolo SR.
    • PLoS One. 2020 Sep 30;15(9):e0239197. doi: 10.1371/journal.pone.0239197.

    • Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
    • Carlson AS, Acevedo RI, Lim DM, Gulati R, Gawne A, Sokolova AO, Cheng HH, Nelson PS, Montgomery RB, Yu EY, Schweizer MT.
    • PLoS One. 2020 Sep 30;15(9):e0239686. doi: 10.1371/journal.pone.0239686.

    • Exploiting Chromosomal Instability of PTEN-Deficient Triple-Negative Breast Cancer Cell Lines for the Sensitization against PARP1 Inhibition in a Replication-Dependent Manner.
    • Cancers (Basel). 2020 Sep 29;12(10):E2809. doi: 10.3390/cancers12102809.

    • First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
    • Yap TA, Tan DSP, Terbuch A, Caldwell R, Guo C, Goh BC, Heong V, Haris NR, Bashir S, Drew Y, Hong DS, Meric-Bernstam F, Wilkinson G, Hreiki J, Wengner AM, Bladt F, Schlicker A, Ludwig M, Zhou Y, Liu L, Bordia S, Plummer R, Lagkadinou E, de Bono JS.
    • Cancer Discov. 2020 Sep 28. doi: 10.1158/2159-8290.CD-20-0868. Epub ahead of print.

    Related:

    Press: Bayer's ATR Inhibitor May Benefit Cancers With ATM Aberrations, Early Data Suggest (Precision Oncology News)

    • PARP Inhibition as Frontline Therapy in Ovarian Cancer.
    • Moore KN, Pothuri B, Monk B, Coleman RL.
    • Clin Adv Hematol Oncol. 2020 Sep;18(8):550-556.

    • LitAlert ~~ GeneLit.com

    • PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
    • Nizialek E, Antonarakis ES.
    • Cancer Manag Res. 2020 Sep 7;12:8105-8114. doi: 10.2147/CMAR.S227033.

    • Recent advancements in PARP inhibitors-based targeted cancer therapy.
    • Zhou P, Wang J, Mishail D, Wang CY.
    • Precis Clin Med. 2020 Sep;3(3):187-201. doi: 10.1093/pcmedi/pbaa030. Epub 2020 Aug 31.

    • Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.
    • Tjokrowidjaja A, Lee CK, Friedlander M, Gebski V, Gladieff L, Ledermann J, Penson R, Oza A, Korach J, Huzarski T, Manso L, Pisano C, Asher R, Lord SJ, Kim SI, Lee JY, Colombo N, Park-Simon TW, Fujiwara K, Sonke G, Vergote I, Kim JW, Pujade-Lauraine E.
    • Eur J Cancer. 2020 Sep 22;139:59-67. doi: 10.1016/j.ejca.2020.08.021. Epub ahead of print.